70/100BIllumina stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Illumina is 252.73, 23.8% above the current price of 204.18. Their targets range from 155.00 to 305.00.
Of the 13 firms that rated Illumina in the past 12 months, 9 rate it buy or strong buy, 2 hold and 2 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 155.00 to 305.00, with an average of 252.73.
| Buy | 9 | |
| Hold | 2 | |
| Sell | 2 |
12-month price target
| Highest target | 305.00 |
| Average target | 252.73 |
| Lowest target | 155.00 |
| Current price | 204.18 |
Illumina price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Illumina price target and rating?
How analysts rate Illumina, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
9 of 13 firms rate it buy now, against 5 of 14 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Illumina analyst upgrades, downgrades and price targets
The latest rating change came on 9 September 2026, when UBS upgraded Illumina from Neutral to Buy. Its price target is 260.00, from 135.00. The most recent new target came from Stephens on 23 October 2026: 275.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 23 Oct 2026 | Stephens | — | 275.00 | — | 268.00 |
| 19 Oct 2026 | Canaccord Genuity | Reiterated · Hold | 205.00 → 300.00 | +46.3% | 262.54 |
| 7 Oct 2026 | Barclays | Reiterated · Underweight | 160.00 → 200.00 | +25.0% | 273.54 |
| 1 Oct 2026 | Guggenheim Subbu Nambi | Reiterated · Buy | 226.00 → 305.00 | +35.0% | 270.81 |
| 29 Sept 2026 | Leerink Partners | Reiterated · Outperform | 210.00 → 300.00 | +42.9% | 273.63 |
| 28 Sept 2026 | Piper Sandler David Westenberg | Reiterated · Overweight | 170.00 → 305.00 | +79.4% | 270.00 |
| 9 Sept 2026 | UBS | Upgraded · Neutral → Buy | 135.00 → 260.00 | +92.6% | 211.06 |
| 3 Sept 2026 | Argus Research | Reiterated · Buy | 235.00 | — | 213.25 |
| 3 Aug 2026 | Canaccord Genuity | Reiterated · Hold | 190.00 → 205.00 | +7.9% | 205.10 |
| 31 Jul 2026 | RBC Capital | Reiterated · Outperform | 170.00 → 230.00 | +35.3% | 199.13 |
| 31 Jul 2026 | Bernstein | — | 185.00 → 215.00 | +16.2% | 205.09 |
| 31 Jul 2026 | Guggenheim | Reiterated · Buy | 200.00 → 226.00 | +13.0% | 205.09 |
| 31 Jul 2026 | Barclays | Reiterated · Underweight | 122.00 → 160.00 | +31.1% | 205.09 |
| 17 Jul 2026 | Leerink Partners Puneet Souda | Reiterated · Outperform | 210.00 | — | 186.89 |
| 14 Jul 2026 | Canaccord Genuity Kyle Mikson | Reiterated · Hold | 140.00 → 190.00 | +35.7% | 190.05 |
| 29 Jun 2026 | Guggenheim | Reiterated · Buy | 180.00 → 200.00 | +11.1% | 176.55 |
| 26 Jun 2026 | Bernstein | — | 185.00 | — | 177.65 |
| 10 Jun 2026 | JP Morgan | Upgraded · Neutral → Overweight | — | — | — |
| 1 Jun 2026 | Guggenheim | Reiterated · Buy | 170.00 → 180.00 | +5.9% | 162.96 |
| 14 May 2026 | RBC Capital | — | 124.00 → 170.00 | +37.1% | 143.24 |
| 14 May 2026 | Daiwa Illumina to Outperform | — | 155.00 | — | 145.00 |
| 1 May 2026 | Canaccord Genuity | Reiterated · Hold | 150.00 → 140.00 | -6.7% | 126.74 |
| 1 May 2026 | Barclays | Reiterated · Underweight | 110.00 → 122.00 | +10.9% | 126.74 |
| 9 Feb 2026 | Piper Sandler | Reiterated · Overweight | 185.00 → 170.00 | -8.1% | 119.72 |
| 6 Feb 2026 | Robert W. Baird Catherine Ramsey Schulte | — | 109.00 → 137.00 | +25.7% | 120.22 |
| 6 Feb 2026 | UBS | — | 120.00 → 135.00 | +12.5% | 121.27 |
| 6 Feb 2026 | Evercore ISI | — | 155.00 → 150.00 | -3.2% | 121.13 |
| 26 Jan 2026 | Guggenheim Subbu Nambi | Reiterated · Buy | 144.00 → 170.00 | +18.1% | 150.38 |
| 26 Jan 2026 | Canaccord Genuity | Reiterated · Hold | 112.00 → 150.00 | +33.9% | 150.28 |
| 20 Jan 2026 | Stifel Nicolaus Daniel Arias | Reiterated · Buy | 155.00 | — | 141.65 |
| 5 Jan 2026 | Evercore ISI Vijay Kumar | — | 142.00 → 155.00 | +9.2% | 138.50 |
| 5 Jan 2026 | Guggenheim | Reiterated · Buy | 144.00 | — | 138.11 |
| 15 Dec 2025 | Barclays | Reiterated · Underweight | 100.00 → 110.00 | +10.0% | 134.85 |
Illumina EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
EPS
Does Illumina beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 94.6% off the result, either way, and their revenue estimate 1.9%, over the last 12 quarters.
- EPS beats
- 81 / 104
- Revenue beats
- 72 / 103
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +93.5%
- Since
- October 2000
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 29 Oct 2026 | 1.36 | 1.62 | +19.1% | 1.15B | 1.17B | +1.1% |
| Q2 FY2026 | 30 Jul 2026 | 1.23 | 1.31 | +6.5% | 1.13B | 1.16B | +2.5% |
| Q1 FY2026 | 30 Apr 2026 | 1.05 | 1.15 | +9.5% | 1.07B | 1.09B | +1.7% |
| Q4 FY2025 | 5 Feb 2026 | 1.24 | 1.35 | +8.9% | 1.12B | 1.16B | +3.6% |
| Q3 FY2025 | 30 Oct 2025 | 1.17 | 1.34 | +14.5% | 1.07B | 1.08B | +1.6% |
| Q2 FY2025 | 31 Jul 2025 | 1.02 | 1.19 | +16.7% | 1.06B | 1.06B | -0.6% |
| Q1 FY2025 | 8 May 2025 | 0.94 | 0.97 | +3.2% | 1.03B | 1.04B | +1.5% |
| Q4 FY2024 | 6 Feb 2025 | 0.92 | 0.86 | -6.5% | 1.07B | 1.10B | +3.0% |
| Q3 FY2024 | 4 Nov 2024 | 0.88 | 1.14 | +29.7% | 1.08B | 1.08B | +0.0% |
| Q2 FY2024 | 6 Aug 2024 | 0.11 | 0.36 | +228.5% | 1.09B | 1.11B | +1.7% |
| Q1 FY2024 | 2 May 2024 | 0.04 | 0.09 | +106.4% | 1.05B | 1.08B | +2.4% |
| Q4 FY2023 | 8 Feb 2024 | 0.02 | 0.14 | +686.1% | 1.09B | 1.12B | +3.1% |
Illumina stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Illumina's earnings keep growing at the 13.4% a year analysts expect to FY2028, it would earn about 9.11 a share in FY2030. At the P/E of similar companies (Medical - Diagnostics & Research, 28.3 to 38.7) that is 258.32 to 352.76 a share, or 302.59 at their average P/E of 33.2. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 5.42 | 153.59 | 179.92 | 209.75 |
| FY2027 | 6.16 | 174.62 | 204.55 | 238.47 |
| FY2028 | 7.08 | 200.71 | 235.11 | 274.09 |
| FY2029 (extrapolated) | 8.03 | 227.70 | 266.72 | 310.95 |
| FY2030 (extrapolated) | 9.11 | 258.32 | 302.59 | 352.76 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 13.4% a year (the analysts' growth, at most 15%). Its own P/E has been above 60, or from losses, too often in the last five years, so bear, base and bull apply the lowest, average and highest P/E of similar companies (Medical - Diagnostics & Research: 28.3, 33.2, 38.7), those up to 60.
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 235.690 | 464.49205Price 235.69627 | +97.1% | |
| 28.860 | 56.2634Price 28.8696 | +94.9% | |
| 199.110 | 384.58163Price 199.112,644 | +93.1% | |
| 123.990 | 237.24178Price 123.99297 | +91.3% | |
| 157.820 | 297.58169Price 157.82471 | +88.6% | |
| 162.670 | 305.52160Price 162.67396 | +87.8% | |
| 216.610 | 405.38304Price 216.61507 | +87.1% |
Furthest below the fair value on each stock's page, updated every day.